--- title: "MedJ 推出國際平台：您可信賴的通往中國快速發展的生物醫學領域的門户" type: "News" locale: "zh-HK" url: "https://longbridge.com/zh-HK/news/281319382.md" description: "MedJ，作為中國領先的醫療媒體平台，推出了其國際平台，這是一個提供中國醫療和生物醫學領域實時洞察的英語中心。該舉措旨在為全球臨牀醫生和研究人員彌補信息差距，突顯中國在生物醫學研究中日益增長的影響力，正如其在 2025 年 NCS 醫院指數中的頂級排名所示。該平台設有創新療法、專家觀點、會議報道和網絡研討會等板塊，促進醫療領域的跨境合作" datetime: "2026-04-01T07:14:30.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/281319382.md) - [en](https://longbridge.com/en/news/281319382.md) - [zh-HK](https://longbridge.com/zh-HK/news/281319382.md) --- # MedJ 推出國際平台：您可信賴的通往中國快速發展的生物醫學領域的門户 SHANGHAI, April 1, 2026 /PRNewswire/ -- MedJ, China's leading medical media platform, today officially launched its dedicated International Platform: a first-of-its-kind authoritative English-language hub delivering real-time, contextualized insights into China's fast-evolving healthcare and biomedical landscape for clinicians, researchers, and industry stakeholders worldwide. The launch comes as China's global influence in biomedical research reaches unprecedented heights. The 2025 NCS Hospital Index, a bibliometric ranking from the editorial teams of _Nature_, _Cell_, and _Science_ (collectively NCS), found 41 hospitals from Chinese mainland ranked in the global top 100 for 2025 publications in the three flagship journals and their high-impact sub-journals. This figure outpaced the U.S. (29 hospitals) to claim the No.1 global spot, underscoring the rising authority of Chinese medical institutions on the world's top academic stage. A trusted leader in China's medical media for over a decade, MedJ serves 3 million registered healthcare professionals, reaches 10 million subscribers, and partners with 20,000+ leading medical experts and 10,000+ hospitals nationwide. Its new International Platform eliminates longstanding barriers for global peers: fragmented information sources, language gaps, and missing critical context around China's medical advances. The platform launches with four core editorial sections: - Innovation Therapy: Full-lifecycle updates on novel drugs, devices, and regulatory milestones in China - Doctors: Exclusive perspectives from China's top clinical and research leaders - Conferences: Frontline reporting from key global medical congresses - Webinar: Live, two-way academic exchanges between Chinese and global medical communities As China solidifies its rightful place in global healthcare, MedJ's International Platform stands as an open, inclusive gateway for cross-border collaboration. All the critical insights you need, in one centralized destination. Visit \[MedJ.cn\] to explore. Contact: MedJ Phone: +86 21 58545118 Mail: medjservice@medj.cn View original content to download multimedia:https://www.prnewswire.com/news-releases/medj-unveils-international-platform-your-trusted-gateway-to-chinas-fast-growing-biomedical-landscape-302730775.html SOURCE MedJ ### 相關股票 - [588860.CN](https://longbridge.com/zh-HK/quote/588860.CN.md) - [159615.CN](https://longbridge.com/zh-HK/quote/159615.CN.md) - [002800.CN](https://longbridge.com/zh-HK/quote/002800.CN.md) - [159837.CN](https://longbridge.com/zh-HK/quote/159837.CN.md) - [560600.CN](https://longbridge.com/zh-HK/quote/560600.CN.md) - [159883.CN](https://longbridge.com/zh-HK/quote/159883.CN.md) - [159992.CN](https://longbridge.com/zh-HK/quote/159992.CN.md) - [159859.CN](https://longbridge.com/zh-HK/quote/159859.CN.md) - [516930.CN](https://longbridge.com/zh-HK/quote/516930.CN.md) - [516820.CN](https://longbridge.com/zh-HK/quote/516820.CN.md) - [513060.CN](https://longbridge.com/zh-HK/quote/513060.CN.md) - [159102.CN](https://longbridge.com/zh-HK/quote/159102.CN.md) - [520690.CN](https://longbridge.com/zh-HK/quote/520690.CN.md) - [159898.CN](https://longbridge.com/zh-HK/quote/159898.CN.md) - [159849.CN](https://longbridge.com/zh-HK/quote/159849.CN.md) - [512290.CN](https://longbridge.com/zh-HK/quote/512290.CN.md) - [516500.CN](https://longbridge.com/zh-HK/quote/516500.CN.md) - [513120.CN](https://longbridge.com/zh-HK/quote/513120.CN.md) - [003008.CN](https://longbridge.com/zh-HK/quote/003008.CN.md) - [159506.CN](https://longbridge.com/zh-HK/quote/159506.CN.md) ## 相關資訊與研究 - [石四藥 (2005):取得國家藥監局有關精氨酸培哚普利片 (5mg) 藥品生產註冊批件](https://longbridge.com/zh-HK/news/287189668.md) - [信達生物：達伯舒® 聯合愛優特® 獲中國國家藥監局批准用於治療晚期或轉移性腎細胞癌患者](https://longbridge.com/zh-HK/news/287186974.md) - [健世科技核心產品 LuX-Valve Plus 歐洲心血管會議公佈數據](https://longbridge.com/zh-HK/news/287133349.md) - [石四藥集團：美阿沙坦鉀已獲中國藥監局批准登記成為在上市製劑使用的原料藥](https://longbridge.com/zh-HK/news/287198604.md) - [鉅子生物掌門年薪千萬，錦波生物業績下滑老闆卻漲薪 300 萬](https://longbridge.com/zh-HK/news/287048605.md)